Cargando…
Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
BACKGROUND: This ancillary study aimed to evaluate (18)F-FDG PET parameter changes after one cycle of treatment compared to baseline in patients receiving first-line neoadjuvant anti-angiogenic nintedanib combined to paclitaxel-carboplatin chemotherapy or chemotherapy plus placebo and to evaluate th...
Autores principales: | Aide, Nicolas, Fauchille, Pauline, Coquan, Elodie, Ferron, Gwenael, Combe, Pierre, Meunier, Jérome, Alexandre, Jerôme, Berton, Dominique, Leary, Alexandra, De Rauglaudre, Gaétan, Bonichon, Nathalie, Pujade Lauraine, Eric, Joly, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113167/ https://www.ncbi.nlm.nih.gov/pubmed/33221969 http://dx.doi.org/10.1007/s00259-020-05092-3 |
Ejemplares similares
-
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
por: Tuefferd, Marianne, et al.
Publicado: (2007) -
Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study
por: Falandry, Claire, et al.
Publicado: (2015) -
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
por: Ray-Coquard, I, et al.
Publicado: (2013) -
En chiva muerta no hay bandidos
por: Hernández Savio, Reynaldo, 1935-
Publicado: (1978) -
Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
por: Chang, Hong, et al.
Publicado: (2023)